HomeClinical TopicsFDA approves new anticlotting drug

FDA approves new anticlotting drug

On January 8, the U.S. Food and Drug Administration (FDA) approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. Read more.


Please enter your comment!
Please enter your name here

Most Recent Content